Photo of Julia H. Hayes,  MD

Julia H. Hayes, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3237


Julia_Hayes@dfci.harvard.edu

Julia H. Hayes, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Medical Oncologist, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research is focused on decision analysis of common clinical scenarios in genitourinary cancers, in particular the screening and treatment of prostate cancer. I am currently constructing a decision analytic model of screening strategies for prostate cancer based on primary data obtained from the European Randomised Study of Screening for Prostate Cancer, and collaborators in Orebro, Sweden. I also focus on treatment options for clinically localized, low-risk prostate cancer. I have recently completed a cost-effectiveness analysis of treatment strategies for low risk prostate cancer that is being used by the Employers Action Coalition on Healthcare (EACH), a group consisting of employers, payers, and providers committed to using the results generated by this model for policy decisions. This work has been presented at ASCO’s Genitourinary Cancers Symposium and in a moderated poster session at ASCO’s Annual Meeting. A completed effectiveness analysis of treatment options for low-risk prostate cancer has just been published.

Publications

Powered by Harvard Catalyst
  • Hayes JH, Nakabayashi M, Kantoff PW. Reply to clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer 2014; 119:4053. PubMed
  • Hayes JH, Barry MJ, McMahon PM. Observation versus initial treatment for prostate cancer. Ann Intern Med 2013; 159:574. PubMed
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, McMahon PM. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med 2013; 158:853-60. PubMed
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012. PubMed
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304:2373-80. PubMed
  • Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010; 106:979-85. PubMed
  • Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010; 116:1887-92. PubMed